Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc. (TBPMF) is a biopharmaceutical company dedicated to discovering and advancing cannabinoid-based medications. Its research and development efforts span crucial medical fields, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features several key drug candidates: PLENITUDE is being developed to address cancer-related pain in advanced-stage patients. REBORN is designed to manage breakthrough cancer pain. Reduvo targets chemotherapy-induced nausea and vomiting. ARDS-003 aims to treat sepsis and prevent acute respiratory distress syndrome. SERENITY is focused on treating cancer cachexia. Further candidates include PPP003 for painful dry eye and uveitis, and HCC011, intended for hepatocellular carcinoma (liver cancer). In a strategic collaboration, Tetra Bio-Pharma has partnered with Cellvera Global Holdings LLC for the joint development of ARDS-003. This endeavor will see ARDS-003 formulated as a combination therapy alongside Qifenda 400MG (Favipiravir), which is a commercially available and widely recognized broad-spectrum antiviral drug. The company's operations are headquartered in Orléans, Canada.